General Practice Doctors in Temple, TX Accepting Medicare

6 General Practice doctors found. Showing 1 - 6

Dr. Omar Steven Arrieta, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: Scott & White 4 South Pedi Administration Rm 431, 2401 South 31st Street, Temple, TX 76508 Phone: 254-724-4363

Dr. Kofi Sarfo-kantanka, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 1605 S 31st St, Temple, TX 76508 Phone: 254-215-0100    Fax: 254-215-0636

Loren C Standlee, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 2027 S 61st St Ste 109, Temple, TX 76504 Phone: 254-228-5291

Dr. Julie Nicole Boisen, MD General Practice Medicare: Medicare Enrolled Practice Location: 2401 S 31st St Bldg 27, Temple, TX 76508 Phone: 254-724-6300

Dr. Joshua Edward Friend, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111

Ms. Valerie H Van Wormer, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 1901 S 1st St, Temple, TX 76504 Phone: 254-743-1844

News Archive

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

Mount Sinai researchers review progress made in using ketamine and other therapies to treat depression

Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy.

Gore provides update on REDUCE Clinical Study of HELEX Septal Occluder for PFO closure

W. L. Gore & Associates (Gore) today provided an update on the Gore REDUCE Clinical Study, a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) closure in patients with history of cryptogenic stroke or imaging-confirmed Transient Ischemic Attack (TIA). The unique study, which includes up to fifty investigational sites in the U.S., Denmark, Finland, Norway and Sweden, is on track to meet its estimated completion in 2015.

New analyses from Esbriet RECAP study in IPF patients presented at ERS 2012

InterMune, Inc. announced that new analyses of data from the RECAP extension study of Esbriet (pirfenidone) were presented today at the 2012 Annual Congress of the European Respiratory Society (ERS) in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

Read more Medical News

› Verified 4 days ago